Core Viewpoint - China National Pharmaceutical Group Modern (国药现代) announced that its subsidiaries, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. and China National Pharmaceutical Group Yixin Pharmaceutical Co., Ltd., have received drug registration certificates from the National Medical Products Administration for two new drugs [1] Group 1: Drug Approvals - China National Pharmaceutical Group Rongsheng's drug, named Midapril Hydrochloride Tablets, is a tablet formulation with a specification of 5mg, classified as a Class 4 chemical drug, with registration certificate number 2025S02225 and approval number H20254897 [1] - China National Pharmaceutical Group Yixin's drug, named Calcium Leucovorin Injection, is an injectable formulation with a specification of 10ml:0.1g (calculated as C H N O), also classified as a Class 4 chemical drug, with registration certificate number 2025S02226 and approval number H20254898 [1]